Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Wegovy, produced average weight loss of 15% in pivotal clinical trials—roughly 22 pounds for a person weighing 150 pounds. Many patients wonder what realistic outcomes look like and whether prescription GLP-1 therapy fits their weight loss goals. PlexusDx delivers clinically-proven semaglutide from licensed 503A compounding pharmacies starting at $149 per month, making personalized weight loss accessible to all 50 states.

Clinical Trial Results for Semaglutide Weight Loss

The landmark STEP trials evaluated semaglutide's effectiveness over 68 weeks in adults with obesity or overweight with at least one weight-related condition. Participants receiving the highest maintenance dose lost approximately 15% of their baseline body weight on average, compared to 2.4% in the placebo group. This 12-percentage-point difference demonstrates semaglutide's ability to produce clinically meaningful weight reduction beyond diet and exercise alone.

Individual results vary based on genetics, adherence, lifestyle factors, and starting dose. Some trial participants achieved greater than 20% weight loss, while others saw modest reductions in the 5-10% range. The dose-escalation protocol used in clinical trials—starting low and increasing gradually—mirrors how PlexusDx physicians manage treatment to balance efficacy and tolerability.

How Individual Weight Loss Varies on Semaglutide

Genetic differences in GLP-1 receptor sensitivity, appetite regulation pathways, and metabolic genes influence how much weight a person loses on semaglutide. Some individuals experience rapid appetite suppression and reach their goal weight in 4-6 months, while others require longer treatment windows or need dose adjustments to optimize results. The PlexusDx Precision Peptide Genetic Test identifies key variants—including GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—that predict peptide-pathway responsiveness.

Body composition, starting weight, and concurrent lifestyle changes also shape outcomes. A 200-pound person may lose 30 pounds while a 150-pound person on the same dose loses 15 pounds. Consistent adherence to injection schedules, increased physical activity, and sustained dietary improvements amplify weight loss beyond medication alone.

Semaglutide Weight Loss Timeline: What to Expect

Most patients begin noticing appetite reduction within the first two weeks of starting semaglutide, though meaningful weight loss typically appears after 4-8 weeks. Weekly weigh-ins are less reliable indicators than monthly trends, as water retention and normal fluctuation can mask progress. By week 12-16, many patients report losing 5-10 pounds and experiencing sustained fullness from smaller meals.

Peak weight loss usually occurs between months 4 and 6, as doses reach therapeutic levels and lifestyle habits solidify. PlexusDx supports this timeline through structured dose escalation protocols—starting at low doses to minimize side effects while gradually increasing to the therapeutic range where maximum efficacy emerges. Continued weight loss beyond six months is possible with sustained treatment and behavioral consistency.

PlexusDx Semaglutide vs. Branded Wegovy: Clinical Equivalence

Compounded semaglutide from licensed 503A pharmacies contains the identical active pharmaceutical ingredient as brand-name Wegovy, manufactured under strict quality standards and FDA oversight. Both delivery mechanisms—branded pens and compounded syringes—produce the same biological effect when dosed correctly. The difference lies in cost: PlexusDx semaglutide injections start at $149 monthly, compared to branded Wegovy's typical $935-$1,299 cash price.

PlexusDx operates in all 50 states without insurance requirements, membership fees, or authorization delays. HSA and FSA accounts cover treatment, expanding accessibility for patients with tax-advantaged savings. Personalized dosing protocols and optional Precision Peptide Genetic Testing help identify whether semaglutide alone, combination therapy, or alternative peptide approaches best align with individual metabolism and genetic predispositions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is 15% weight loss realistic for me on semaglutide?

Clinical trials show 15% as the average outcome, but individual results span 5-25% depending on genetics, starting weight, adherence, and lifestyle factors. PlexusDx physicians use Precision Peptide Genetic Testing to identify your genetic profile across 49 peptides and 14 pathways, helping predict whether semaglutide alone or a combination approach (such as GLP-Squared, which pairs semaglutide with tirzepatide) aligns better with your metabolic predispositions.

How long does it take to see weight loss results on semaglutide?

Most patients experience appetite suppression within 1-2 weeks and measurable weight loss by week 4-8. Significant results typically appear between months 3-6 as doses reach therapeutic levels. PlexusDx supports structured dose escalation to balance safety and efficacy, meaning your dose may increase over time—but your price remains flat at $149 per month.

Can I afford semaglutide without insurance?

PlexusDx semaglutide injections start at $149 monthly with no membership fees, insurance requirement, or hidden costs. Treatment qualifies for HSA and FSA accounts, reducing your net expense further. Unlike branded Wegovy at $900+, compounded semaglutide from licensed 503A pharmacies delivers clinical equivalence at an accessible price across all 50 states.

What happens if I stop losing weight on semaglutide?

Weight-loss plateaus occur when the body adapts to medication and calorie deficit. Dose increases, lifestyle adjustments, or combination therapy (such as adding tirzepatide via GLP-Squared) can restart progress. PlexusDx physicians monitor your response and adjust your regimen; your subscription price remains stable regardless of dose escalation.

Does genetic testing predict my weight loss on semaglutide?

The PlexusDx Precision Peptide Genetic Test identifies variants in GLP1R, GIPR, FTO, and MC4R that influence appetite regulation, satiety response, and metabolic rate—all factors affecting semaglutide efficacy. This $99 add-on test maps 150+ genetic insights across 14 pathways, helping your physician personalize treatment selection and predict whether semaglutide monotherapy or dual-peptide approaches optimize your individual outcomes.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves